145 related articles for article (PubMed ID: 8843172)
1. Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients.
Riccio A; Lisato G; de Kreutzenberg SV; Marchetto S; Turrin M; Tiengo A; Del Prato S
Metabolism; 1996 Oct; 45(10):1196-202. PubMed ID: 8843172
[TBL] [Abstract][Full Text] [Related]
2. Assessment of hepatic insulin action in obese type 2 diabetic patients.
Staehr P; Hother-Nielsen O; Levin K; Holst JJ; Beck-Nielsen H
Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
Cusi K; Consoli A; DeFronzo RA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
[TBL] [Abstract][Full Text] [Related]
4. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
Groop LC; Bonadonna RC; DelPrato S; Ratheiser K; Zyck K; Ferrannini E; DeFronzo RA
J Clin Invest; 1989 Jul; 84(1):205-13. PubMed ID: 2661589
[TBL] [Abstract][Full Text] [Related]
5. Fatty acids mediate the acute extrahepatic effects of insulin on hepatic glucose production in humans.
Lewis GF; Vranic M; Harley P; Giacca A
Diabetes; 1997 Jul; 46(7):1111-9. PubMed ID: 9200644
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of acute and chronic hypoglycemic action of gliclazide.
da Tos V; Maran A; Vigili de Kreutzenberg S; Marchetto S; Tadiotto F; Bettio M; Marescotti MC; Tiengo A; Del Prato S
Acta Diabetol; 2000; 37(4):201-6. PubMed ID: 11450504
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
Wajchenberg BL; Santomauro AT; Giannella-Neto D; Borghi VC; Porrelli RN
Diabetes Res Clin Pract; 1992 Aug; 17(2):89-97. PubMed ID: 1425152
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
[TBL] [Abstract][Full Text] [Related]
9. Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production.
Barzilai N; Hawkins M; Angelov I; Hu M; Rossetti L
Diabetes; 1996 Oct; 45(10):1329-35. PubMed ID: 8826967
[TBL] [Abstract][Full Text] [Related]
10. Glucagon does not increase plasma free fatty acid and glycerol concentrations in patients with noninsulin-dependent diabetes mellitus.
Jeng CY; Sheu WH; Jaspan JB; Polonsky KS; Chen YD; Reaven GM
J Clin Endocrinol Metab; 1993 Jul; 77(1):6-10. PubMed ID: 8100832
[TBL] [Abstract][Full Text] [Related]
11. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
Nielsen MF; Wise S; Dinneen SF; Schwenk WF; Basu A; Rizza RA
Diabetes; 1997 Dec; 46(12):2007-16. PubMed ID: 9392488
[TBL] [Abstract][Full Text] [Related]
12. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
Perriello G; Misericordia P; Volpi E; Santucci A; Santucci C; Ferrannini E; Ventura MM; Santeusanio F; Brunetti P; Bolli GB
Diabetes; 1994 Jul; 43(7):920-8. PubMed ID: 8013758
[TBL] [Abstract][Full Text] [Related]
13. Abnormal transient rise in hepatic glucose production after oral glucose in non-insulin-dependent diabetic subjects.
Thorburn A; Litchfield A; Fabris S; Proietto J
Diabetes Res Clin Pract; 1995 May; 28(2):127-35. PubMed ID: 7587920
[TBL] [Abstract][Full Text] [Related]
14. Exogenous insulin replacement in type 2 diabetes reverses excessive hepatic glucose release, but not excessive renal glucose release and impaired free fatty acid clearance.
Woerle HJ; Popa E; Dostou J; Welle S; Gerich J; Meyer C
Metabolism; 2002 Nov; 51(11):1494-500. PubMed ID: 12404204
[TBL] [Abstract][Full Text] [Related]
15. Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats.
Dachicourt N; Bailbé D; Gangnerau MN; Serradas P; Ravel D; Portha B
Eur J Pharmacol; 1998 Nov; 361(2-3):243-51. PubMed ID: 9865514
[TBL] [Abstract][Full Text] [Related]
16. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.
Koopmans SJ; Kushwaha RS; DeFronzo RA
Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109
[TBL] [Abstract][Full Text] [Related]
17. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.
Matsuda M; Defronzo RA; Glass L; Consoli A; Giordano M; Bressler P; Delprato S
Metabolism; 2002 Sep; 51(9):1111-9. PubMed ID: 12200754
[TBL] [Abstract][Full Text] [Related]
18. The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat.
Tanira MO; Furman BL
Pharmacol Res; 1999 May; 39(5):349-56. PubMed ID: 10328992
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group.
Kelley DE; Henry RR; Edelman SV
Diabetes Care; 1996 Nov; 19(11):1237-42. PubMed ID: 8908387
[TBL] [Abstract][Full Text] [Related]
20. Hepatic sensitivity to insulin: effects of sulfonylurea drugs.
Del Prato S; Vigili de Kreutzenberg S; Riccio A; Tiengo A
Am J Med; 1991 Jun; 90(6A):29S-36S. PubMed ID: 1872301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
